Risk Factors Predicting the Postoperative Outcome in 134 Patients with Active Endocarditis
Background: Surgery remains the cornerstone in management of endocarditis.
Methods: In this retrospective cohort we evaluated the operative outcome of patients with infective endocarditis. The SPSS program was used to analyze the data.
Results: A total of 134 predominantly male patients (60%) with a mean age of 55 ± 12.4 years were examined. The procedures included single valve (n = 88; 66%), double/multiple valves (n = 29; 22%), and valve-coronary artery bypass graft (CABG) (n = 16; 12%). Perioperative mortality was 11.9% (n = 16). In the multivariate analysis, dialysis (odds ratio [OR] = 7.88; 95% confidence interval [CI] [1.78-34.77]; P = .006), sepsis (OR = 19.5; 95% CI [2.76-137.9]; P = .002), and perfusion time (95% CI [1.00-1.02]; P = .003) were independent predictors of perioperative mortality. The overall long-term survival at 28 months was 69.2% ± 4%. Dialysis (P = .0001) was a predictor of mortality, whereas elevated creatinine in nondialysis patients (P = .0002) was not. In the multivariate analysis, dialysis (hazard ratio [HR] 4.06%; 95% CI [0.936-8.526]; P = .0002), CABG (HR 2.32; 95% CI [1.086-4.978]; P = .0299), chronic obstructive pulmonary disease (HR 2.20; 95% CI [1.027-4.739]; P = .0426), and double/multiple valve procedure (HR 3.0; 95% CI [1.467-6.206]; P = .0027) were risk factors for long-term mortality.
Conclusion: Renal failure but not renal insufficiency is a risk factor for short and long-term mortality.
Forrest GN, Arnold RS, Gammie JS, Gilliam BL. 2011. Single center experience of a vancomycin resistant enterococcal endocarditis cohort. J Infect 63:420-8.nFunakoshi S, Kaji S, Yamamuro A, et al. 2011. Impact of early surgery in the active phase on long-term outcomes in left-sided native valve infective endocarditis. J Thorac Cardiovasc Surg 142:836-42.e1.nGutierrez-Martin MA, Galvez-Aceval J, Araji OA. 2010. Indications for surgery and operative techniques in infective endocarditis in the present day. Infect Disord Drug Targets 10:32-46.nKang DH, Kim YJ, Kim SH, et al. 2012. Early surgery versus conventional treatment for infective endocarditis. N Engl J Med 366:2466-73.nKiefer T, Park L, Tribouilloy C, et al. 2011. Association between valvular surgery and mortality among patients with infective endocarditis complicated by heart failure. JAMA 306:2239-47.nLeone S, Ravasio V, Durante-Mangoni E, et al. 2012. Epidemiology, characteristics, and outcome of infective endocarditis in Italy: the Italian Study on Endocarditis. Infection 40:527-35.nLopez J, Revilla A, Vilacosta I, et al. 2011. Multiple-valve infective endocarditis: clinical, microbiologic, echocardiographic, and prognostic profile. Medicine 90:231-6.nManne MB, Shrestha NK, Lytle BW, et al. 2012. Outcomes after surgical treatment of native and prosthetic valve infective endocarditis. Ann Thorac Surg 2012;93:489-93.nMeszaros K, Nujic S, Sodeck GH, et al. 2012. Long-term results after operations for active infective endocarditis in native and prosthetic valves. Ann Thorac Surg 94:1204-10.nMokhles MM, Ciampichetti I, Head SJ, Takkenberg JJ, Bogers AJ. 2011. Survival of surgically treated infective endocarditis: a comparison with the general Dutch population. Ann Thorac Surg 91:1407-12.nMokhles MM, Ciampichetti I, van Domburg R, Cheng JM, Bogers AJ, Witsenburg M. 2012. Infective endocarditis in a tertiary referral hospital: long-term follow up. J Heart Valve Dis 21:118-24.nOhara T, Nakatani S, Kokubo Y, et al. 2012. Clinical predictors of in-hospital death and early surgery for infective endocarditis: results of CArdiac Disease REgistration (CADRE), a nation-wide survey in Japan. Int J Cardiol 67:2688-94.nRankin JS, Milford-Beland S, O'Brien SM, et al. 2007. The risk of valve surgery for endocarditis in patients with dialysis-dependent renal failure. J Heart Valve Dis 16:617-22; discussion 22.nSheikh AM, Elhenawy AM, Maganti M, Armstrong S, David TE, Feindel CM. 2009. Outcomes of double valve surgery for active infective endocarditis. J Thorac Cardiovasc Surg 138:69-75.nTamura K, Arai H, Yoshizaki T. 2012. Long-term outcome of active infective endocarditis with renal insufficiency in cardiac surgery. Ann Thorac Cardiovasc Surg 18:216-21.nPolat A, Tuncer A, Tuncer EY, et al. 2012. Surgical treatment of culture-negative aortic infective endocarditis. Ann Thorac Surg 93:44-9.nShang E, Forrest GN, Chizmar T, et al. 2009. Mitral valve infective endocarditis: benefit of early operation and aggressive use of repair. Ann Thorac Surg 87:1728-33; discussion 1734.nThuny F, Giorgi R, Habachi R, et al. 2012. Excess mortality and morbidity in patients surviving infective endocarditis. Am Heart J 164:94-101.nWang A. 2011. Recent progress in the understanding of infective endocarditis. Curr Treat Options Cardiovasc Med 13:586-94.nYamaguchi H, Eishi K. 2007. Surgical treatment of active infective mitral valve endocarditis. Ann Thorac Cardiovasc Surg 13:150-5.n
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).